Non-viral Gene Delivery Methods for Bone and Joints

Viral carrier transport efficiency of gene delivery is high, depending on the type of vector. However, viral delivery poses significant safety concerns such as inefficient/unpredictable reprogramming outcomes, genomic integration, as well as unwarranted immune responses and toxicity. Thus, non-viral...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioengineering and biotechnology Vol. 8; p. 598466
Main Authors Gantenbein, Benjamin, Tang, Shirley, Guerrero, Julien, Higuita-Castro, Natalia, Salazar-Puerta, Ana I, Croft, Andreas S, Gazdhar, Amiq, Purmessur, Devina
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Viral carrier transport efficiency of gene delivery is high, depending on the type of vector. However, viral delivery poses significant safety concerns such as inefficient/unpredictable reprogramming outcomes, genomic integration, as well as unwarranted immune responses and toxicity. Thus, non-viral gene delivery methods are more feasible for translation as these allow safer delivery of genes and can modulate gene expression transiently both , , and . Based on current studies, the efficiency of these technologies appears to be more limited, but they are appealing for clinical translation. This review presents a summary of recent advancements in orthopedics, where primarily bone and joints from the musculoskeletal apparatus were targeted. In connective tissues, which are known to have a poor healing capacity, and have a relatively low cell-density, i.e., articular cartilage, bone, and the intervertebral disk (IVD) several approaches have recently been undertaken. We provide a brief overview of the existing technologies, using nano-spheres/engineered vesicles, lipofection, and electroporation. Here, delivery for microRNA (miRNA), and silencing RNA (siRNA) and DNA plasmids will be discussed. Recent studies will be summarized that aimed to improve regeneration of these tissues, involving the delivery of bone morphogenic proteins (BMPs), such as BMP2 for improvement of bone healing. For articular cartilage/osteochondral junction, non-viral methods concentrate on targeted delivery to chondrocytes or MSCs for tissue engineering-based approaches. For the IVD, growth factors such as GDF5 or GDF6 or developmental transcription factors such as or FOXF1 seem to be of high clinical interest. However, the most efficient method of gene transfer is still elusive, as several preclinical studies have reported many different non-viral methods and clinical translation of these techniques still needs to be validated. Here we discuss the non-viral methods applied for bone and joint and propose methods that can be promising in clinical use.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Ilia Bozo, Federal Medical and Biological Agency of Russia, Russia; Umberto Galderisi, University of Campania Luigi Vanvitelli, Italy
This article was submitted to Preclinical Cell and Gene Therapy, a section of the journal Frontiers in Bioengineering and Biotechnology
These authors have contributed equally to this work
ORCID: Benjamin Gantenbein, orcid.org/0000-0002-9005-0655; Shirley Tang, orcid.org/0000-0001-8807-2348; Julien Guerrero, orcid.org/0000-0003-4130-4230; Natalia Higuita-Castro, orcid.org/0000-0002-3297-6281; Ana I. Salazar-Puerta, orcid.org/0000-0003-4954-6226; Andreas S. Croft, orcid.org/0000-0003-1472-1979; Amiq Gazdhar, orcid.org/0000-0002-4807-8785; Devina Purmessur, orcid.org/0000-0002-7445-1678
Edited by: Georg A. Feichtinger, University of Leeds, United Kingdom
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2020.598466